Recently, the FDA approved leucovorin, a generic medication, for a rare brain disorder. However, this decision has sparked some controversy, particularly concerning claims about its effectiveness for autism. The drug is intended for individuals with a genetic condition that restricts folate delivery to the brain. This condition is extremely rare, affecting fewer than 1 in a million people in the U.S.
This approval contrasts sharply with earlier statements from President Trump and FDA officials, who suggested leucovorin could significantly benefit children with autism. They mentioned that up to half of children with autism might have this folate-related issue. However, senior FDA officials later clarified that their assessment was based on limited evidence, which focused solely on the drug’s effects on patients with the rare condition.
Dr. Alycia Halladay of the Autism Science Foundation emphasized that there’s no solid proof supporting leucovorin’s safety or effectiveness for most autistic individuals. The lack of a confirmed figure for how many kids with autism have this condition makes things even more complicated. Some doctors are using unapproved lab tests to diagnose it, which adds an extra layer of confusion.
Last fall, a White House event underscored the government’s commitment to understanding autism, with promises from Health Secretary Robert F. Kennedy Jr. about exploring its causes. But now, the scientific community is urging caution regarding leucovorin’s use for autism. The American Academy of Pediatrics does not recommend it routinely for children with autism, noting that the potential risks, including irritability and aggression, outweigh the benefits.
A recent study published in The Lancet drew attention to a significant increase—71%—in leucovorin prescriptions for children aged 5 to 17 in the months following the initial announcements about the drug. David Mandell, an autism expert, highlighted the confusion this has created for families trying to navigate the best care for their children.
Interestingly, while the FDA is now allowing foreign manufacturers to import leucovorin to boost supply, the original manufacturer, GSK, has no plans to re-release its version. Many families are now grappling with difficulties in getting prescriptions filled, leading to frustration and an increased demand for the drug.
Experts stress that parents considering leucovorin should be aware of potential side effects and the uncertain benefits. The idea behind its use is that some autistic individuals may have antibodies blocking folate from reaching the brain, but experts note that even non-autistic family members can have those antibodies.
In the end, while the search for effective treatments for autism continues, the narrative around leucovorin serves as a reminder of the complexities in medical science and the importance of evidence-based practices. The road ahead will require careful evaluation, ongoing research, and a commitment to clarity for families navigating these challenging waters.
Source link
Medication, Autism, Donald Trump, Robert F. Kennedy Jr., U.S. Food and Drug Administration, General news, AP Top News, Marty Makary, David Mandell, Washington news, Business, Alycia Halladay, Health, Science
